Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?

• Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to treat agitation associated with dementia due to Alzheimer’s disease, backed by Phase 3 ADVANCE-1 and ACCORD-2 data.
• The AUVELITY label expansion creates a new opportunity in Alzheimer’s-related agitation, a highly prevalent, costly, and difficult-to-manage symptom, while Axsome prepares a June launch supported by an enlarged 630-person sales force and broad expected Medicare Part D coverage.
• We’ll now examine how AUVELITY’s new Alzheimer’s agitation indication, and Axsome’s expanded commercial push, reshape the company’s investment narrative.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Axsome Therapeutics Investment Narrative Recap

To own Axsome today, you have to believe its focused CNS portfolio, led by Auvelity and Sunosi, can eventually support a path to profitability despite ongoing net losses and heavy commercial spend. The new Alzheimer’s agitation label is a clear short term catalyst, but it also amplifies reliance on Auvelity at a time when losses widened to US$64.54 million in Q1 2026, keeping execution and payer pressure as key risks.

The most relevant recent development here is the FDA approval of Auvelity for agitation in dementia due to Alzheimer’s disease, supported by the ADVANCE-1 and ACCORD-2 Phase 3 trials. This label expansion slots directly into Axsome’s existing commercial buildout, including the 630 person sales force and broad expected Medicare Part D coverage, and now sits alongside other late stage efforts like solriamfetol and AXS-14 as a core driver of the next phase of catalysts.

However, investors should also be aware that...

Read the full narrative on Axsome Therapeutics (it's free!)

Axsome Therapeutics' narrative projects $2.5 billion revenue and $932.4 million earnings by 2029.

Uncover how Axsome Therapeutics' forecasts yield a $266.94 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Before this approval, the most optimistic analysts were already modeling Axsome’s revenue reaching about US$2.5 billion and earnings of roughly US$1.4 billion by 2028, which is a much more aggressive view than consensus and assumes that late stage programs like AXS 05 in Alzheimer’s agitation all hit their marks, so this new label could either reinforce or challenge that story depending on how the launch actually performs.

Explore 8 other fair value estimates on Axsome Therapeutics - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Axsome Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com